UPDATE - Argus Research Initiates Equity Research Report Coverage on Aptorum Group Limited (NasdaqGM: APM)
April 30 2019 - 10:42AM
Argus Research, an independent investment research firm, has
launched Equity Research Report coverage on Aptorum Group Limited
(NasdaqGM: APM)
Click here to view Full Argus
Report
Highlights, as conveyed by Argus Analyst Steve Silver,
include:
COMPANY HIGHLIGHTS
- APM: Addressing Orphan Indications and Unmet Needs
- In our view, Aptorum has compiled an impressive pipeline of
early-stage assets that we expect to drive significant value, both
from internal development and external collaborations.
- In mid-2018, Aptorum launched a medical clinic in Hong Kong.
Over time, we expect revenue from this business to help mitigate
the company’s R&D cash burn.
- In December 2018, Aptorum raised approximately $11 million from
an initial public offering. The Company ended 2018 with $27.1
million in cash/restricted cash and marketable securities, which
should be sufficient to advance at least one of its lead clinical
programs to Phase I trials.
- Based on our sum-of-the-parts NPV valuation for the company’s
lead programs and IP and technology assets, we arrive at a fair
value estimate of $24 per share, well above current
levels.
INVESTMENT THESIS (partial excerpts below:
click here to view the full Argus Report)
Aptorum Group Ltd., based in Hong Kong, is developing a range of
therapeutic and diagnostic technologies to treat unmet medical
needs. Its primary focus areas include infectious diseases,
neurology, gastroenterology, and oncology. Aptorum is also
developing product candidates in surgical robotics and medical
devices. In mid-2018, the company launched an outpatient clinic in
Hong Kong to treat chronic diseases resulting from modern sedentary
lifestyles and an aging population.
Amid an improving regulatory backdrop for antibacterial
therapeutics, we see the potential for ALS-4 to advance rapidly
through clinical development and to become Aptorum’s lead program.
ALS-4 is a small molecule aimed at treating bacterial infections
caused by Staphylococcus aureus, including MRSA. MRSA is a
difficult-to-treat, hospital-acquired pathogen, often referred to
as a “super bug,” that is a worldwide cause of morbidity and
mortality. In the U.S. alone, MRSA is associated with more than
100,000 hospitalizations and approximately 19,000 deaths annually,
according to the company. ALS-4 is the first product candidate to
apply chemical genetics to tackle MRSA infection. The company’s
development team won the Innovation Academy Award at the 4th
International Conference on Prevention & Infection Control
(ICPIC
2017).
About Aptorum Group Limited (NasdaqGM: APM)
(www.aptorumgroup.com):
Aptorum Group Ltd., a Hong Kong-based pharmaceutical company,
develops and commercializes therapeutic and diagnostic
technologies to treat unmet medical needs. The company also focuses
on the development of surgical robotics and medical devices and
operates outpatient clinics.
APM Investor Relations Contact:Sabrina
KhanChief Financial OfficerTel: +852 2117
6611Email: investor.relations@aptorumgroup.com
About Argus Research Corp. Headquartered in
NYC, Argus Research (www.argusresearch.com) is a leading
independent equity research firm (est. 1934) ̶ providing
fundamental and quantitative research coverage on more than 1,500
companies across all 11 sectors of the S&P 500, as well as
macroeconomic and equity market forecasts, thematic research, model
portfolios and pre-IPO research. In addition, Argus has
recently committed to providing a sponsored research solution for
small & mid-cap companies seeking coverage. Our Asset
Management, Bank Trust, sell-side advisor and self-directed
investor clients value Argus’s proprietary equity research
methodology, analysis and commentary. Argus’s Equity
Research/earnings estimates are available on major research /
earnings estimate aggregator platforms, including Bloomberg,
Thomson Reuters, Factset and S&P Global.
For more Information,
contact: Darrell
Stone646-747-5438dstone@argusresearch.com
Argus Research Co. has received a flat fee from the company
discussed in this report as part of a Sponsored Research agreement
between Argus and the company. No part of Argus Research’s
compensation is directly or indirectly related to the content of
this assessment or to other opinions expressed in this report.
Please refer to the full Argus report and the disclaimer for
complete disclosures.
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Apr 2023 to Apr 2024